U.S. DOJ Seeks Medicaid Pricing Data From Ranbaxy
This article was originally published in PharmAsia News
Ranbaxy Laboratories has come under the scrutiny of the U.S. Justice Department, which seeks documents and pricing data covering the drugs it supplies under the Medicaid program.
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.